Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma

Yago Nieto, MD, PhD, Nina Shah, MD, Uday R Popat, MD, Roy B Jones, PhD MD, Qaiser Bashir, MD, Rolland Bassett, MS, Benigno C. Valdez, PhD, Borje S Andersson, MD, PhD, Simrit Parmar, MD, Robert Z. Orlowski, M.D., Ph.D, Jatin J. Shah, M.D., Sheeba K. Thomas, M.D., Michael Wang, M.D., Richard E Champlin, MD, Muzaffar Qazilbash, M.D.

Blood (2013) 122 (21): 3346.

https://doi.org/10.1182/blood.V122.21.3346.3346

Published: 2013

Journal Articles

Biological Significance of the Immumoproteasome Subunits Mecl-1 and LMP-2 in Diffuse Large B-Cell Lymphoma.

Lan V Pham, PhD, Alex Rollo, Archito T. Tamayo, MS, John Lee, MD, Zhuang Zuo, MD, Ph.D, Luhong Sun, MD, PhD, Liang Zhang, MD, PhD, Zhishou Ou, MD, Luis E Fayad, MD, Michael Wang, M.D., Richard J. Ford, MD, PhD

Blood (2012) 120 (21): 2717.

https://doi.org/10.1182/blood.V120.21.2717.2717

Published: 2012

Journal Articles

A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials.

David S. Siegel, MD, PhD, Michael Wang, M.D., Thomas G Martin, III, MD, Jeffrey R. Infante, MD, Jonathan L. Kaufman, MD, Kanya Ranjangam, MD, PhD, Mei Huang, MS, Elizabeth Bilotti, MSN, RN, Ravi Vij, MD

Blood (2012) 120 (21): 2962.

https://doi.org/10.1182/blood.V120.21.2962.2962

Published: 2012

Journal Articles

Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib.

Michael Wang, M.D., Leslie Popplewell, MD, Robert H. Collins, Jr., MD, Jane N. Winter, MD, Andre Goy, MD, Anna Robeva, MS, Nicoletta Pirotta, Jenna Fan, Judith Klimovsky, MD, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 2751.

https://doi.org/10.1182/blood.V120.21.2751.2751

Published: 2012

Journal Articles

Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study

Nathan H Fowler, MD, Sattva S. Neelapu, MD, Fredrick B Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Robert Z. Orlowski, M.D., Ph.D., Michael Wang, M.D., Francesco Turturro, MD, Yasuhiro Oki, MD, Linda Catherine Lacerte, RN, Felipe Samaniego, MD, MPH

Blood (2012) 120 (21): 901.

https://doi.org/10.1182/blood.V120.21.901.901

Published: 2012

Journal Articles

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Michael Wang, M.D., Simon A. Rule, MD, Peter Martin, MD, Andre Goy, MD, Rebecca Auer, MD, Brad S. Kahl, M.D., Wojciech Jurczak, Ranjana H. Advani, MD, Jorge Enrique E Romaguera, MD, Jesse McGreivy, MD, Fong Clow, ScD, Michelle Stevens-Brogan, Lori Kunkel, MD, Kristie A. Blum, MD

Blood (2012) 120 (21): 904.

https://doi.org/10.1182/blood.V120.21.904.904

Published: 2012

Journal Articles

Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma

Jatin J. Shah, M.D., Robert Z. Orlowski, M.D., Ph.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Michael Wang, M.D., Muzaffar H. Qazilbash, MD, Uday R. Popat, M.D., Simrit Parmar, M.D., Nina Shah, MD, Qaiser Bashir, Richard E. Champlin, Donna M. Weber, M.D.

Blood (2012) 120 (21): 75.

https://doi.org/10.1182/blood.V120.21.75.75

Published: 2012

Journal Articles

High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up

Simrit Parmar, M.D., Joshua Howell, PharmD, Michael Wang, M.D., Mubeen A Khan, Qaiser Bashir, MD, Jatin J. Shah, M.D., Nina Shah, MD, Uday R. Popat, M.D., Sergio A Giralt, MD, Robert Z. Orlowski, M.D., Ph.D., Muzaffar Qazilbash, M.D.

Blood (2012) 120 (21): 750.

https://doi.org/10.1182/blood.V120.21.750.750

Published: 2012

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia

Isere Kuiatse, Ph.D., Sheeba K. Thomas, MD, Donna M. Weber, M.D., Adam M. Stein, B.S., Michael Wang, M.D., Jatin J. Shah, M.D., Steven P. Treon, M.D., Ph.D., Stephen M. Ansell, M.D., Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 3723.

https://doi.org/10.1182/blood.V120.21.3723.3723

Published: 2012

Journal Articles

Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Jatin J. Shah, M.D., Sheeba K. Thomas, MD, Donna M. Weber, M.D., Michael Wang, M.D., Raymond Alexanian, M.D., Muzaffar H. Qazilbash, MD, Qaiser Bashir, MD, Simrit Parmar, M.D., Nina Shah, MD, Uday R. Popat, M.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 4081.

https://doi.org/10.1182/blood.V120.21.4081.4081

Published: 2012

Journal Articles

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Jatin J. Shah, M.D., Donna M. Weber, M.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Michael Wang, M.D., Muzaffar H. Qazilbash, MD, Simrit Parmar, M.D., Nina Shah, MD, Qaiser Bashir, MD, Uday R. Popat, M.D., Brandi Hilder, Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 4082.

https://doi.org/10.1182/blood.V120.21.4082.4082

Published: 2012

Journal Articles

Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.

Stephan Joseph Dorkhom, D.O., Shadia Zaman, Ph.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, M.D., Martha L. Anderson, R.N., Veerabhadran Baladandayuthapani, Ph.D., Yan Heather Lin, Ph.D., Min Fu, Ph.D., Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha V. Gandhi, Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 2976.

https://doi.org/10.1182/blood.V120.21.2976.2976

Published: 2012

Journal Articles

Activation of the Wnt/β-Catenin Pathway Mediates Lenalidomide Resistance in Multiple Myeloma.

Chad C. Bjorklund, Ph.D., Deborah J. Kuhn, Ph.D., B.Sc., Jairo A. Matthews, B.A., Michael Wang, M.D., Veerabhadran Baladandayuthapani, Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2009) 114 (22): 113.

https://doi.org/10.1182/blood.V114.22.113.113

Published: 2009

Journal Articles

Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma.

Qaiser Bashir, Peter Thall, Chitra Hosing, Floralyn L Mendoza, Eric Han, Michael Wang, M.D., Jatin Shah, MD, Amin Alousi, MD, Paolo Anderlini, Partow Kebriaei, Issa F. Khouri, Uday Popat, MD, Marcos de Lima, MD, Richard Champlin, MD, Sergio A Giralt, MD, Muzaffar H Qazilbash

Blood (2009) 114 (22): 1186.

https://doi.org/10.1182/blood.V114.22.1186.1186

Published: 2009

Journal Articles

Inhibition of Interleukin-6 Signaling with CNTO 328 Sensitizes Plasma Cell Dyscrasias to the Effects of Melphalan in Association with Suppression of Signaling through Protein Kinase B/Akt.

Sally A. Hunsucker, Ph.D., Valeria Magarotto, M.D., Jairo A. Matthews, B.A., Michael Wang, M.D., Veerabhadran Baladandayuthapani, Ph.D., Peter M. Voorhees, M.D., Hong Xie, M.D., Mark Cornfeld, M.D., M.P.H., Jeffrey A. Nemeth, M.D., Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2009) 114 (22): 1836.

https://doi.org/10.1182/blood.V114.22.1836.1836

Published: 2009

Journal Articles

Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups.

Sheeba K Thomas, M.D., Lei Feng, M.S., Kay B Delasalle, B.S., Michael Wang, M.D., Jatin J Shah, M.D., Robert Z Orlowski, M.D., Ph.D., Raymond Alexanian, M.D., Donna M Weber, M.D.

Blood (2009) 114 (22): 1668.

https://doi.org/10.1182/blood.V114.22.1668.1668

Published: 2009

Journal Articles

Bortezomib Resistance Is Mediated by Increased Signaling through the Insulin-Like Growth Factor-1/Akt Axis.

Deborah J. Kuhn, Ph.D., Chad C. Bjorklund, Ph.D., Valeria Magarotto, M.D., Jairo A. Matthews, B.A., Michael Wang, M.D., Veerabhadran Baladandayuthapani, Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2009) 114 (22): 2739.

https://doi.org/10.1182/blood.V114.22.2739.2739

Published: 2009

Journal Articles

Triggering of Toll-Like Receptor 4 Expression in Human Multiple Myeloma Promotes Proliferation and Protects the Cells From Immune and Chemotherapy Drug Attack.

Zhen Cai, Hanying Bao, Lijuan Wang, PhD, Yang Yang, PhD, Yi Zhao, PhD, Donghua He, PhD, Peilin Lu, MD, PhD, Michael Wang, M.D.

Blood (2009) 114 (22): 2843.

https://doi.org/10.1182/blood.V114.22.2843.2843

Published: 2009

Journal Articles

Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.

Blood (2007) 110 (11): 620.

https://doi.org/10.1182/blood.V110.11.620.620

Published: 2007

NARROW

High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma

Biological Significance of the Immumoproteasome Subunits Mecl-1 and LMP-2 in Diffuse Large B-Cell Lymphoma.

A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials.

Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib.

Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma

High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia

Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.

Activation of the Wnt/β-Catenin Pathway Mediates Lenalidomide Resistance in Multiple Myeloma.

Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma.

Inhibition of Interleukin-6 Signaling with CNTO 328 Sensitizes Plasma Cell Dyscrasias to the Effects of Melphalan in Association with Suppression of Signaling through Protein Kinase B/Akt.

Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups.

Bortezomib Resistance Is Mediated by Increased Signaling through the Insulin-Like Growth Factor-1/Akt Axis.

Triggering of Toll-Like Receptor 4 Expression in Human Multiple Myeloma Promotes Proliferation and Protects the Cells From Immune and Chemotherapy Drug Attack.

Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only